RDR Alert®

OCS-05 meets primary safety endpoints and demonstrates a neuroprotective structural benefit, as well as visual improvement, in topline results from ACUITY.

On October 25, 2024, Kind Pharmaceutical announced receipt of FDA Orphan Drug Designation for AND017 in the treatment of sickle cell disease.

The 24-month data showed a notable response rate in study eyes treated with a high dose of AGTC-501, with a generally safe and tolerable clinical profile.

OCU400 gene therapy remained safe and tolerable across different mutation and dose cohorts in retinitis pigmentosa and Leber congenital amaurosis.

Based on the regulatory feedback provided by the FDA, Nanoscope announced plans to initiate Biologics License Application submission in Q1 2025.

This September 2024 month in review highlights recent advances in gene therapies and therapies demonstrating the potential for improved vision outcomes.

Ascendis Pharma has submitted a sBLA to the FDA for TransCon hGH for the treatment of adults with growth hormone deficiency.

Individuals diagnosed with retinitis pigmentosa experienced an elevated risk of depressive disorder, compared with the general Korean population.

Announced on September 24, 2024, the approval marks the second treatment approved by the FDA for Niemann-Pick disease type C within one week.

Arimoclomol, in combination with miglustat, is approved to treat neurological symptoms associated with NPC in adults and children aged ≥2 years.

Better known as brittle bone disease, osteogenesis imperfecta can cause severe respiratory distress at birth and longterm effect to respiratory function. Morello shares his team's research into the cause of this effect.

Nanoscope Therapeutics announced the meeting with the FDA supported the advancement of MCO-010 into Phase 3 for Stargardt disease.

The agency's designation was granted to plozasiran as an adjunct to diet to reduce triglycerides in adults with familial chylomicronemia syndrome.

ATSN-101 was well tolerated 12 months after treatment and demonstrated on average, a 100-fold improvement in vision, with some improved by 10,000-fold.

Analysis of the Phase 3 explorer7 study indicates a preference for concizumab prophylaxis over no prophylaxis in patients with hemophilia A or B with inhibitors.

Axatilimab was awarded approval for the treatment of chronic GVHD in adult and pediatric patients who failed ≥2 prior lines of systemic therapy.

Ravulizumab therapy may enable patients with PNH to achieve activity and patient-reported outcomes comparable to the US general population.

Ocugen will initiate expanded access to OCU400 gene therapy in adults with retinitis pigmentosa prior to BLA approval.

Giroctocogene fitelparvovec achieved primary and key secondary objectives of superiority compared to routine prophylaxis in hemophilia A treatment.

One-year 1/2 data examines the safety and efficacy of OCU400 gene therapy for the treatment of retinitis pigmentosa.

Topline Phase 2b/3 results show high- and low-dose MCO-010 treatment improved BCVA compared to control through 100 weeks.

Mirum Pharmaceuticals submitted an NDA for chenodiol tablets to treat CTX based on positive phase 3 RESTORE trial results.

Long-term Phase 2 data demonstrate KP104's potential as an optimal first-line monotherapy for PNH.

Patients with AATD had increased cardiovascular risk compared to non-AATD COPD and healthy controls, with results suggesting physiological tests may assess risk more accurately.

A Veterans Affairs study finds low alpha-1 antitrypsin phenotyping rates, indicating the need for improved healthcare provider education on AATD.

FDA approves mavorixafor (XOLREMDI) for WHIM syndrome, the first approved treatment for the rare disease.

Abeona's pz-cel is up for indicated use to treat patients with recessive dystrophic epidermolysis bullosa.

Katie Abouzahr, MD, explains the transformative potential of nipocalimab for the treatment of patients with autoantibody-driven conditions.

The phase 2b trial showed a statistically significant improvement of BCVA at week 52 in both the high-dose and low-dose MCO-010 cohorts compared with sham.